Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers

Journal of Clinical Pharmacology

Volumn 46, Issue 9, 2006, Pages 991-998

  Faessel, Hélène M ^a   Smith, Bill J ^a   Gibbs, Megan A ^a   Gobey, Jason S ^a   Clark, David J ^a   Burstein, Aaron H ^a  

^a PFIZER INC   (United States)

Author keywords

Evening dosing; Food effect; Single dose pharmacokinetics; Varenicline

Indexed keywords

NICOTINIC AGENT; PARTIAL AGONIST; PLACEBO; VARENICLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LIVER MICROSOME METABOLISM; MALE; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SINGLE DRUG DOSE; SMOKING; SMOKING CESSATION; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG TOXICITY; FEMALE; HEALTH; HUMANS; MALE; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; RECEPTORS, NICOTINIC; SMOKING;

EID: 33747072313     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006290669     Document Type: Article

References (15)

1. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet. 2003;362:847-852.
2. Quantifying selected major risks to health. World Health Report 2002. Geneva, Switzerland: World Health Organization, 2002. Available at: http://www.who.int/whr/2002/en/whr02_ch4.pdf.
3. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328:1519.
4. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004;306:1029-1032.
5. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998;391:173-177.
6. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48:3474-3477.
7. Srivastava ED, Russell MAH, Feyerabend C, Masterson JG, Rhodes J. Sensitivity and tolerance to nicotine in smokers and nonsmokers. Psychopharmacology. 1991;105:63-68.
8. Perkins KA, Gerlach D, Broge M, et al. Dissociation of nicotine tolerance from tobacco dependence in humans. J Pharmacol Exp Ther. 2001;296:849-856.
9. Perkins KA, Grobe JE, Fonte C, et al. Chronic and acute tolerance to subjective, behavioral and cardiovascular effects of nicotine in humans. J Pharmacol Exp Ther. 1994;270:628-638.
10. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121-130.
11. Zevin S, Benowitz NL. Drug Interactions with tobacco smoking: an update. Clin Pharmacokinet. 1999;36:425-438.
12. Benowitz NL, Jacob P III. Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther. 1993;53:316-323.
13. Rowland M, Tozer TN. Clinical Pharmacokinetics. Philadelphia, Pa: Lea & Febiger; 1989.
14. Martinez MN, Amidon GL. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol. 2002;42:620-643.
15. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. 1999;36:233-254.